Developer docs
API playgroundTry for free, no card

Search company profiles

age1

Full company profile

uuid0002ws9

Namestring
age1
Legal namestring
Age1 Capital Management, LLC
Websiteurl
age1.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Age1 Capital Management, LLC (operates as age1) is a San Francisco-based venture capital firm that invests exclusively in early-stage companies developing therapeutics, tools, and technologies intended to extend healthy human lifespan. The firm writes checks ranging from $500,000 to $4M at the earliest stages of company formation — angel, pre-seed, seed, and Series A — and prefers to lead rounds to control terms on behalf of founders. age1 was launched in 2019 as the successor vehicle to The Longevity Fund and a prior AGE1 accelerator experiment, with the explicit mission of building a pragmatic, rigorous, and optimistic longevity community.

The firm's core products are its investment services and curated portfolio. As of the latest data, the portfolio includes approximately 20 longevity-biotech companies spanning canine longevity (Loyal), RNAi delivery across the blood-brain barrier (Aerska), bone regeneration (Skeletalis), neurodegeneration interventions (Aperture Tx, Conception), induced proximity medicines (General Proximity), regenerative hearing/gene therapies (Decibel Therapeutics), gene editing (Precision BioSciences), immune checkpoint therapies (ALX Oncology), GI/liver disease therapeutics (Metacrine), mTORC1 modulators (Navitor Pharma), AI-led drug discovery (Fauna Bio, Anagenex), and additional stealth and The Longevity Fund-backed companies. The firm emphasizes follow-on support through later rounds and offers co-working space and a talent network as portfolio resources.

Economically, age1 generates returns through equity ownership and carried interest on portfolio exits, including multiple IPO exits through The Longevity Fund lineage (ALXO, DBTX, MTCR, DTIL, UBX). The firm operates as a private LLC domiciled in Delaware, is led by co-founders Alex Colville (General Partner) and Laura Deming (Venture Partner), and supports a small operating team of roughly eight people. Customer relationships are bifurcated: portfolio founders receive capital and support, while limited partners provide committed capital in exchange for exposure to longevity-biotech venture returns.

Short descriptiontext

age1 is a San Francisco-based early-stage venture capital firm that funds founders building therapeutics, tools, and technologies targeting aging and age-related disease, writing $500K-$4M checks from angel through Series A stages and preferring lead positions with founder-friendly terms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, longevity biotech funding, early-stage investment, seed to series A, biotech portfolio management
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Investment Management
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns / Carried Interest
TypeLicensing Royalties
Description

Age1 generates returns through equity ownership in portfolio companies, benefiting from carried interest on successful exits including IPOs and acquisitions. The firm has had multiple portfolio companies achieve IPO exits including ALX Oncology (ALXO), Decibel Therapeutics (DBTX), Metacrine (MTCR), Precision BioSciences (DTIL), and Unity Biotechnology (UBX).

age1.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Pricing details1 tier
1Early-stage investment checks from $500K to $4M
ModelOtherBilling cadenceMulti-year contract
Notes

Check sizes range from $500,000 to $4 million depending on round dynamics. They invest at angel, pre-seed, seed, and Series A stages.

age1.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

age1 is an early-stage venture capital firm that invests in longevity biotechnology companies developing therapeutics, tools, and technologies targeting aging and age-related disease to extend healthy lifespan. The firm writes checks ranging from $500,000 to $4 million at the angel, pre-seed, seed, and Series A stages, generally prefers to lead rounds, and is well-capitalized to follow portfolio companies through later rounds. Beyond capital, age1 provides strategic support and fosters a pragmatic, rigorous, and optimistic longevity founder community.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

age1 is a venture capital firm (not a product company) that funds breakthrough longevity companies. The firm's core offering is its investment services, writing checks from $500,000 to $4M at the earliest stages (angel through Series A). The firm has built a portfolio of longevity-focused biotech companies including Loyal (developing LOY-002, a canine lifespan extension drug), Aerska (RNAi medicines targeting brain diseases via blood-brain barrier delivery), Skeletalis (bone regeneration therapies), and approximately 20 other portfolio companies spanning epigenetics, senolytics, regenerative medicine, and longevity diagnostics. The portfolio includes companies backed by age1 as well as The Longevity Fund (a predecessor vehicle).

Product and service3 records
1age1 Venture Capital Services
CategoryVenture Capital Investment
Description

Venture capital investment services for early-stage longevity and biotech companies, writing checks from $500,000 to $4M at the angel, pre-seed, seed, and Series A stages and preferring to lead rounds.

2Longevity Portfolio Companies
CategoryInvestment Portfolio
Description

Portfolio of longevity-focused biotech companies backed by age1 and The Longevity Fund, including Loyal (canine longevity drugs), Aerska (RNAi medicines for brain diseases), Skeletalis, Aperture Tx, and others spanning neurodegeneration, regenerative medicine, and aging research.

3San Francisco Co-Working Space
CategoryFounder Workspace
Description

Co-working space at age1's downtown San Francisco office offered to portfolio founders as part of the firm's founder-support offering.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

age1's predecessor fund, also founded by Laura Deming, focused exclusively on early-stage longevity biotech. Most direct comparable: shares thesis, founder base, and several portfolio companies (combined as "age1 + The Longevity Fund" on the portfolio page).

TypeDirect peer
Description

European-based venture firm dedicated exclusively to aging and longevity biotech investing. Closest thematic peer to age1 globally — both pursue seed-to-Series A longevity bets with biology-first conviction under single-thesis focus.

TypeDirect peer
Description

Early-stage venture firm investing in longevity, biotechnology, and rejuvenation technologies. Directly comparable as a longevity-focused VC with similar check sizes and stage orientation.

TypeDirect peer
Description

Healthcare and biotech-focused venture firm founded by Bill Maris (ex-Google Ventures). Comparable as an early-stage health/longevity-adjacent VC with founder-friendly terms and similar early check size profile.

TypeBroad incumbent
Description

Established biotech VC operating across stages with significant longevity portfolio exposure (e.g., co-invested alongside age1/Longevity Fund portfolio companies). Comparable as a biotech-native generalist investor participating in the same capital stacks.

TypeBroad incumbent
Description

Healthcare and biotech-focused investment firm with both early- and later-stage activity. Comparable as an institutional biotech VC participating in longevity-adjacent rounds and capable of leading later-stage financings.

TypeBroad incumbent
Description

Large tech/biotech venture firm with longevity exposure and long-duration founder-friendly underwriting style. Comparable as a broad incumbent writing early-stage checks in transformative tech and biology — a potential co-investor or competitor for longevity rounds.

TypeBroad incumbent
Description

Tech-focused VC (Peter Thiel) with explicit interest in life extension and longevity moonshots. Comparable as a brand-led firm comfortable with high-conviction, contrarian bets at the intersection of frontier science and venture returns.

TypeBroad incumbent
Description

Biotech-specific vehicle of Andreessen Horowitz investing from seed to clinical stage across therapeutics platforms. Comparable as a well-capitalized broad incumbent that age1's successful portfolio companies may turn to for later-stage rounds.

TypeBroad incumbent
Description

Multi-stage life sciences investment platform with both venture and growth capacity. Comparable as a large incumbent biotech investor — a likely follow-on capital provider and potential LP source for age1's future funds.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment6 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

age1

Venture Capital / Investment Managementage1.com

age1 is a San Francisco-based early-stage venture capital firm that funds founders building therapeutics, tools, and technologies targeting aging and age-related disease, writing $500K-$4M checks from angel through Series A stages and preferring lead positions with founder-friendly terms.

What age1 does

Age1 Capital Management, LLC (operates as age1) is a San Francisco-based venture capital firm that invests exclusively in early-stage companies developing therapeutics, tools, and technologies intended to extend healthy human lifespan. The firm writes checks ranging from $500,000 to $4M at the earliest stages of company formation — angel, pre-seed, seed, and Series A — and prefers to lead rounds to control terms on behalf of founders. age1 was launched in 2019 as the successor vehicle to The Longevity Fund and a prior AGE1 accelerator experiment, with the explicit mission of building a pragmatic, rigorous, and optimistic longevity community.

The firm's core products are its investment services and curated portfolio. As of the latest data, the portfolio includes approximately 20 longevity-biotech companies spanning canine longevity (Loyal), RNAi delivery across the blood-brain barrier (Aerska), bone regeneration (Skeletalis), neurodegeneration interventions (Aperture Tx, Conception), induced proximity medicines (General Proximity), regenerative hearing/gene therapies (Decibel Therapeutics), gene editing (Precision BioSciences), immune checkpoint therapies (ALX Oncology), GI/liver disease therapeutics (Metacrine), mTORC1 modulators (Navitor Pharma), AI-led drug discovery (Fauna Bio, Anagenex), and additional stealth and The Longevity Fund-backed companies. The firm emphasizes follow-on support through later rounds and offers co-working space and a talent network as portfolio resources.

Economically, age1 generates returns through equity ownership and carried interest on portfolio exits, including multiple IPO exits through The Longevity Fund lineage (ALXO, DBTX, MTCR, DTIL, UBX). The firm operates as a private LLC domiciled in Delaware, is led by co-founders Alex Colville (General Partner) and Laura Deming (Venture Partner), and supports a small operating team of roughly eight people. Customer relationships are bifurcated: portfolio founders receive capital and support, while limited partners provide committed capital in exchange for exposure to longevity-biotech venture returns.

age1 firmographics

Firmographics
Name
age1
Legal name
Age1 Capital Management, LLC
Website
https://age1.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
age1 is a San Francisco-based early-stage venture capital firm that funds founders building therapeutics, tools, and technologies targeting aging and age-related disease, writing $500K-$4M checks from angel through Series A stages and preferring lead positions with founder-friendly terms.
Ownership category
akta.pro rank

Where age1 is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

age1 business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Investment Returns / Carried Interest: Age1 generates returns through equity ownership in portfolio companies, benefiting from carried interest on successful exits including IPOs and acquisitions. The firm has had multiple portfolio companies achieve IPO exits including ALX Oncology (ALXO), Decibel Therapeutics (DBTX), Metacrine (MTCR), Precision BioSciences (DTIL), and Unity Biotechnology (UBX).

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEarly-stage investment checks from $500K to $4M

Go-to-market motion1 record

Marketing channels5 records

age1 product offering

Product offering

Core offering

age1 is an early-stage venture capital firm that invests in longevity biotechnology companies developing therapeutics, tools, and technologies targeting aging and age-related disease to extend healthy lifespan. The firm writes checks ranging from $500,000 to $4 million at the angel, pre-seed, seed, and Series A stages, generally prefers to lead rounds, and is well-capitalized to follow portfolio companies through later rounds. Beyond capital, age1 provides strategic support and fosters a pragmatic, rigorous, and optimistic longevity founder community.

Product overview

age1 is a venture capital firm (not a product company) that funds breakthrough longevity companies. The firm's core offering is its investment services, writing checks from $500,000 to $4M at the earliest stages (angel through Series A). The firm has built a portfolio of longevity-focused biotech companies including Loyal (developing LOY-002, a canine lifespan extension drug), Aerska (RNAi medicines targeting brain diseases via blood-brain barrier delivery), Skeletalis (bone regeneration therapies), and approximately 20 other portfolio companies spanning epigenetics, senolytics, regenerative medicine, and longevity diagnostics. The portfolio includes companies backed by age1 as well as The Longevity Fund (a predecessor vehicle).

Differentiator

Problem solved

Functional benefit

Products and services

  • age1 Venture Capital Services Venture capital investment services for early-stage longevity and biotech companies, writing checks from $500,000 to $4M at the angel, pre-seed, seed, and Series A stages and preferring to lead rounds.
  • Longevity Portfolio Companies Portfolio of longevity-focused biotech companies backed by age1 and The Longevity Fund, including Loyal (canine longevity drugs), Aerska (RNAi medicines for brain diseases), Skeletalis, Aperture Tx, and others spanning neurodegeneration, regenerative medicine, and aging research.
  • San Francisco Co-Working Space Co-working space at age1's downtown San Francisco office offered to portfolio founders as part of the firm's founder-support offering.

Companies that use age1

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

age1 technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

age1 partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

age1 competitors and assessment

Company assessment

Direct peers

  • The Longevity Fund: age1's predecessor fund, also founded by Laura Deming, focused exclusively on early-stage longevity biotech. Most direct comparable: shares thesis, founder base, and several portfolio companies (combined as "age1 + The Longevity Fund" on the portfolio page).
  • Apollo Ventures: European-based venture firm dedicated exclusively to aging and longevity biotech investing. Closest thematic peer to age1 globally — both pursue seed-to-Series A longevity bets with biology-first conviction under single-thesis focus.
  • Longevity Vision Fund: Early-stage venture firm investing in longevity, biotechnology, and rejuvenation technologies. Directly comparable as a longevity-focused VC with similar check sizes and stage orientation.
  • Section32: Healthcare and biotech-focused venture firm founded by Bill Maris (ex-Google Ventures). Comparable as an early-stage health/longevity-adjacent VC with founder-friendly terms and similar early check size profile.

Broad incumbents

  • ARCH Venture Partners: Established biotech VC operating across stages with significant longevity portfolio exposure (e.g., co-invested alongside age1/Longevity Fund portfolio companies). Comparable as a biotech-native generalist investor participating in the same capital stacks.
  • Foresite Capital: Healthcare and biotech-focused investment firm with both early- and later-stage activity. Comparable as an institutional biotech VC participating in longevity-adjacent rounds and capable of leading later-stage financings.
  • Khosla Ventures: Large tech/biotech venture firm with longevity exposure and long-duration founder-friendly underwriting style. Comparable as a broad incumbent writing early-stage checks in transformative tech and biology — a potential co-investor or competitor for longevity rounds.
  • Founders Fund: Tech-focused VC (Peter Thiel) with explicit interest in life extension and longevity moonshots. Comparable as a brand-led firm comfortable with high-conviction, contrarian bets at the intersection of frontier science and venture returns.
  • Andreessen Horowitz Bio Fund: Biotech-specific vehicle of Andreessen Horowitz investing from seed to clinical stage across therapeutics platforms. Comparable as a well-capitalized broad incumbent that age1's successful portfolio companies may turn to for later-stage rounds.
  • Bain Capital Life Sciences: Multi-stage life sciences investment platform with both venture and growth capacity. Comparable as a large incumbent biotech investor — a likely follow-on capital provider and potential LP source for age1's future funds.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

age1 social profiles

Digital presence

age1 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

age1 leadership team

Management profile

Number of profiles

Profiles8 records

age1 funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

age1 M&A and investment

M&A and investment

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about age1

What does age1 do?

age1 is an early-stage venture capital firm that invests in longevity biotechnology companies developing therapeutics, tools, and technologies targeting aging and age-related disease to extend healthy lifespan. The firm writes checks ranging from $500,000 to $4 million at the angel, pre-seed, seed, and Series A stages, generally prefers to lead rounds, and is well-capitalized to follow portfolio companies through later rounds. Beyond capital, age1 provides strategic support and fosters a pragmatic, rigorous, and optimistic longevity founder community.

Is age1 a public or private company?

age1 is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was age1 founded?

age1 was founded in 2019. It employs 1 to 10 people.

Where is age1 based?

age1 is headquartered in San Francisco, United States, in the North America region.

How does age1 make money?

One revenue line is on record: investment Returns / Carried Interest.

Who are age1's main competitors?

Direct peers on record are The Longevity Fund, Apollo Ventures, Longevity Vision Fund and Section32. Broad incumbents are ARCH Venture Partners, Foresite Capital, Khosla Ventures, Founders Fund, Andreessen Horowitz Bio Fund and Bain Capital Life Sciences.

Does age1 have an API?

No public API is recorded for age1.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Silicon Republic10 Irish medtech start-ups innovating the gameTen Irish medtech start-ups are highlighted for their innovations, including Aerska, Amply, and Coroflo, with funding rounds and expansion plans. Ireland exports about €15bn of medtech products annually to over 100 destinations. The list covers companies developing RNA medicines, AI drug discovery, and wearable devices.Business Wire BlogLoyal Raises $100M Series C, Led by age1, to Advance the First Canine Longevity DrugLoyal, a clinical-stage animal health company developing lifespan extension drugs for dogs, has raised $100M in Series C funding led by age1, with participation from Baillie Gifford, bringing total investment in the company to over $250M since its founding in 2019. The funding will support advancement of LOY-002 toward FDA Expanded Conditional Approval, with two of three major requirements already complete and the final submission planned for later this year. The company is also scaling its team and building distribution channels in preparation for market launch of what would be the first FDA-approved drug for lifespan extension in any species.LoyalLoyal’s Series C: $100M to advance the first longevity drugLoyal announced a $100 million Series C funding round led by age1 and Laura Deming's The Longevity Fund, with participation from Baillie Gifford, to advance LOY-002 toward FDA approval as what the company describes as the first longevity drug for senior dogs. The company has completed two of three major requirements for FDA Expanded Conditional Approval, including safety and efficacy acceptance, and has fully enrolled its pivotal STAY study with over 1,300 dogs across 70 veterinary clinics nationwide. The funding will support final regulatory work, team expansion, and preparation for commercial launch, marking Loyal's transition from research to market readiness.MorningstarLoyal Raises $100M Series C, Led by age1, to Advance the First Canine Longevity DrugLoyal, a clinical-stage animal health company, raised $100M in Series C funding led by age1, with participation from Baillie Gifford, bringing total investment to over $250M since 2019. The funding will advance LOY-002, a prescription daily pill for senior dogs targeting metabolic drivers of aging, which has completed two of three major requirements for FDA Expanded Conditional Approval and could become the first FDA-approved lifespan extension drug in any species. The company also completed enrollment in the STAY study, the largest clinical trial in veterinary medicine history with 1,300 dogs across 70 clinics, and plans to submit its final regulatory requirement later this year.Venture Capital Access OnlineLoyal Raises $100M Series C, Led by age1, to Advance the First Canine Longevity DrugLoyal, a clinical-stage animal health company developing lifespan extension drugs for dogs, has raised $100M in Series C funding led by age1, with participation from Baillie Gifford and existing investors, bringing total investment to over $250M since its founding in late 2019. The funding will support Loyal's lead program LOY-002 through remaining FDA requirements for Expanded Conditional Approval, with the company planning to submit its final major requirement later this year. LOY-002, a prescription daily pill for senior dogs, has already completed two of three major requirements and could become the first FDA-approved drug for lifespan extension in any species.GlobeNewswireAerska Raises $39M Series A Financing led by EQT Dementia Fund and age1 to Systemically Deliver RNA Medicines to the BrainAerska closed a $39 million Series A financing led by EQT Dementia Fund and age1, bringing total funds to $60 million. The proceeds will advance its brain shuttle technology for systemically delivered RNAi therapeutics targeting neurological diseases. The company aims to progress toward clinical trials for Alzheimer's and other brain disorders.BioSpaceAerska Raises $39M Series A Financing led by EQT Dementia Fund and age1 to Systemically Deliver RNA Medicines to the BrainAerska, a biotechnology company developing RNA medicines for CNS diseases using brain shuttle technology, closed a $39 million Series A financing round led by EQT Dementia Fund and age1, with participation from Iaso Ventures. The funding brings the company's total raised capital to $60 million since launch, months after its seed round in October 2025, with proceeds supporting advancement of its antibody-oligo conjugate platform toward clinical development for neurological diseases. As part of the financing, representatives from the lead investors—including Arno de Wilde and Philip Scheltens from EQT, and Alex Colville from age1—will join Aerska's Board of Directors.GlobeNewswireAerska Raises $39M Series A Financing led by EQT Dementia Fund and age1 to Systemically Deliver RNA Medicines to the BrainAerska, a biotechnology company developing RNA medicines for CNS diseases, announced the close of a $39 million Series A financing round led by EQT Dementia Fund and age1, with participation from Iaso Ventures. This brings the company's total funds raised to $60 million since its launch, months after its October 2025 seed funding. The funding will advance Aerska's antibody-oligo conjugate platform using brain shuttle technology to deliver RNAi therapeutics across the blood-brain barrier for treating neurological diseases.proofing companiesEQT Life Sciences co-leads USD 39 million Series A inEQT Life Sciences co-led a USD 39 million Series A financing round in Aerska, a biotechnology company pioneering RNA medicines for neurological diseases using brain shuttle technology. The funding, which brings Aerska's total raised to USD 60 million, will advance its antibody-oligo conjugate platform designed to deliver RNA interference therapeutics across the blood-brain barrier. As part of the financing, representatives from EQT Life Sciences and age1 will join Aerska's Board of Directors.LinkedInAfter building Ochre Bio, Jack O'Meara's newest biotech raises $21M for neuro siRNAsAerska, a biotech company developing RNA medicines for central nervous system diseases, has publicly launched with $21 million in seed financing co-led by age1, BACKED VC, and Speedinvest, with participation from BlueYard Capital, Lingotto, Norrsken, Kerna Ventures, PsyMed Ventures, Ada Ventures, and Saras Capital. The funding will support development of the company's 'brain shuttle' technology designed to enable systemic administration of RNA medicines to the brain. The company was founded by Jack O'Meara, who previously built Ochre Bio.